Roivant拓展Brepocitinib研发计划:启动LPP新2B/3期试验并公布Batoclimax治疗TED的3期研究结果

美股速递
Apr 02

Roivant Sciences Ltd. (ROIV) 宣布扩大其候选药物Brepocitinib的研发计划,将针对扁平苔藓样糠疹(LPP)开展一项新的2B/3期临床试验。同时,公司还公布了另一款药物Batoclimab用于治疗甲状腺眼病(TED)的3期研究结果。

此次战略扩展彰显了Roivant致力于推进其创新疗法管线,以解决未满足的医疗需求。新启动的LPP试验旨在评估Brepocitinib对这一罕见炎症性瘢痕性脱发疾病的疗效与安全性。而Batoclimab在TED领域的积极3期数据,则为该药物的潜在应用提供了重要支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10